valueequityanalysis.com

Independent, business-by-business valuations built from company filings — owner earnings, a ten-year outlook, and a bear / base / bull range. Search a ticker to see our estimate of what the business is worth.

Not investment advice. We are not registered investment advisers, and the people behind this site may hold or trade positions in companies analyzed here. Full disclosures.

TransUnion (TRU) stock intrinsic value fair value estimate & owner earnings analysis

Margin of safety$24.00 ComplexityAverage Updated
$16.00 $67.00
bear $16.00 base $39.00 bull $67.00 margin of safety $24.00 market price* $74.08
TransUnion is one of the three national credit bureaus in the United States. It sells credit data, analytics and identity/fraud tools to lenders, insurers and other businesses (Financial Services and Emerging Verticals), plus consumer credit-monitoring products (Consumer Interactive). It also operates in Canada, Latin America, the United Kingdom, Africa, India and Asia Pacific; the International segment was $1,011.0 million of $4,576.3 million of 2025 revenue. Revenue has grown every year of the last decade, from $1.7 billion in 2016 to $4.6 billion in 2025, helped by the Callcredit (2018) and Neustar (2021) acquisitions and by the 2021 sale of the Healthcare business. How we measure earnings: we start from operating cash flow, strip out swings in working capital, and subtract stock compensation ($145.6 million in 2025) and the capital spending needed to keep the business running (about $296 million of $326.0 million in 2025). On that basis owner earnings per share were roughly $1.96 (2017), $2.11, $2.76, $2.58, $3.07, $2.51 (2022), $1.64 (2023), $2.42 (2024) and $3.88 (2025). Two items matter. In 2022, $435 million of cash left through other liabilities, mainly taxes on the Healthcare sale gain, and we treat that as timing, not a running cost. In 2025, other liabilities and receivables also absorbed cash ($127.6 million and $119.4 million); we removed these as working capital, which lifts the 2025 figure, so 2025 is not a clean run rate. We anchor on the 2022 to 2025 median, about $2.46 per share, because the business changed with the Healthcare sale and the Neustar purchase and carries its current debt load only since then. Owner earnings grew about 60% in 2025; our base case assumes 4% in year one, well below that, because it does not count on a repeat of the mortgage-driven jump. Acquired-intangible amortization is large (total depreciation and amortization was $574.8 million in 2025). It is a non-cash charge and is added back, but we let it hold the growth path down rather than treating acquired customer relationships as permanent. The 2023 impairment of $414.0 million on the U.K. business is a reminder that acquisitions have not always earned their price; it is also non-cash. Base case, about $39 per share: owner earnings grow 4% a year for three years, 3% for three, then 2% for four, reaching about $3.27 per share in year ten, then hold flat for another fifteen years and end there. The growth credited is the pace this business has already delivered in a steady record of revenue growth through varied conditions; the flat period reflects the credit-bureau position that has persisted. Left out: the pending purchase of a controlling stake in Trans Union de Mexico (not yet closed), new products, share gains and margin expansion, none of which is secured. Bear case, about $16 per share: owner earnings fall back to the $1.64 of 2023 and stay there with no growth, then end after fifteen years. The evidence is that it has happened: 2023 was the trough, mortgage-related price and volume gains in Financial Services (revenue up 17.5% in 2025, led by Mortgage pricing) can reverse, and the company carries $5.1 billion of debt, with $1.1 billion maturing in 2029, so refinancing costs could squeeze cash. Regulation is a live exposure: TransUnion is under a 2023 consent order with the CFPB and FTC (it paid $11.0 million in redress and $4.0 million in penalties), and the earlier CFPB lawsuit over the 2017 order was dismissed in March 2025. Bull case, about $67 per share: the 2025 level of $3.88 per share proves durable, grows 5% a year for five years and 3% for the next five, then holds flat for fifteen years. This assumes pricing and volume gains in Financial Services and Emerging Verticals (up 8.5% in 2025) continue at the pace of the last two years. These are values for the equity as a whole; we do not subtract debt again, since owner earnings are already after interest. What would make this wrong: a sustained fall in credit-data volumes or prices, higher interest costs on the refinancing, or tighter regulation of credit reporting. The margin-of-safety price is $24 per share, well below the middle case, because of the leverage, mortgage sensitivity and regulatory exposure.
Fiscal yearOwner's earningsMethodology
2025 $3.88 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$987.6M; WC cash effect=$(217.6)M (AR -119.4, other assets -1.9, AP +31.3, other liabilities -127.6), removed; SBC=$145.6M; capex=$326.0M, growth capex=$29.8M (7.6% x revenue change $392.5M) so maintenance capex=$296.2M; OE=$763.4M; diluted shares=196.6M; OE/sh=$3.88. Reconciliation: net income 469.9 + D&A 574.8 + SBC 145.6 + deferred taxes (28.8) + other 43.7 = $1,205.2M = CFO less WC effect; less SBC and maintenance capex = $763.4M (no gap). Source: FY2025 10-K acc. 0001552033-26-000012.
2024 $2.42 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$832.5M; WC cash effect=$(53.7)M, removed; SBC=$121.2M; capex=$315.8M, growth capex=$26.8M (7.6% x revenue change $352.6M) so maintenance capex=$289.0M; OE=$476.0M; diluted shares=196.7M; OE/sh=$2.42. Source: FY2024 10-K acc. 0001552033-25-000015; FY2025 10-K acc. 0001552033-26-000012.
2023 $1.64 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$645.4M; WC cash effect=$(73.9)M, removed; SBC=$100.3M; capex=$310.7M, growth capex=$9.2M (7.6% x revenue change $121.3M) so maintenance capex=$301.5M; OE=$317.5M; diluted shares=193.4M; OE/sh=$1.64. Goodwill impairment $414.0M (UK) is non-cash and already excluded via CFO. Source: FY2023 10-K acc. 0001552033-24-000027; FY2025 10-K acc. 0001552033-26-000012.
2022 $2.51 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$297.2M; WC cash effect=$(511.2)M, removed (includes $(435.3)M other liabilities, driven mainly by taxes paid on the 2021 Healthcare divestiture gain per the 10-K); SBC=$82.8M; capex=$298.2M, growth capex=$57.0M (7.6% x revenue change $749.7M) so maintenance capex=$241.2M; OE=$484.4M; diluted shares=193.1M; OE/sh=$2.51. Source: FY2022 10-K acc. 0001552033-23-000016.
2021 $3.07 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$808.3M; WC cash effect=$(44.9)M, removed; SBC=$69.2M; capex=$224.2M, growth capex=$32.7M (7.6% x revenue change $429.6M, continuing-ops basis) so maintenance capex=$191.5M; OE=$592.5M; diluted shares=193.0M; OE/sh=$3.07. Source: FY2022 10-K acc. 0001552033-23-000016.
2020 $2.58 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$787.6M (as restated for Healthcare divestiture in FY2022 10-K); WC cash effect=+$47.1M (subtracted); SBC=$44.3M; capex=$205.6M, growth capex=$4.6M (7.6% x revenue change $60.5M on the originally reported basis) so maintenance capex=$201.0M; OE=$495.2M; diluted shares=192.2M; OE/sh=$2.58. Source: FY2022 10-K acc. 0001552033-23-000016 and FY2020 10-K acc. 0001552033-21-000008.
2019 $2.76 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$776.7M; WC cash effect=+$22.8M (subtracted); SBC=$51.0M; capex=$198.5M, growth capex=$25.8M (7.6% x revenue change $338.9M) so maintenance capex=$172.7M; OE=$530.2M; diluted shares=191.8M; OE/sh=$2.76. Source: FY2019 10-K acc. 0001552033-20-000014.
2018 $2.11 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$555.7M; WC cash effect=$(55.4)M, removed; SBC=$57.9M; capex=$180.1M, growth capex=$29.1M (7.6% x revenue change $383.4M) so maintenance capex=$151.0M; OE=$402.2M; diluted shares=190.9M; OE/sh=$2.11. Source: FY2018 10-K acc. 0001552033-19-000010.
2017 $1.96 ▼
OE = CFO - working capital movement - SBC - maintenance capex. CFO=$465.8M; WC cash effect=$(57.3)M (AR 44.7, other assets 59.8 outflows; AP +9.7, other liabilities +37.5), removed; SBC=$33.1M; capex=$135.3M, growth capex=$17.4M (7.6% avg capex/revenue x revenue change $228.9M) so maintenance capex=$117.9M; OE=$372.1M; diluted shares=189.9M; OE/sh=$1.96. Source: FY2017 10-K acc. 0001552033-18-000018 (as carried in later filings).

Owner's earnings per share by fiscal year, most recent first. Tap a row to see how that figure was calculated, including the source filing.

Sales geography
United States (about 78% of 2025 revenue, nationwide); International segment (about 22%): Canada, Latin America (including Colombia, Brazil, Dominican Republic, Chile, Guatemala), United Kingdom, Africa, India and Asia Pacific
Historical growth strategy

We don't have historical growth strategy information for this company yet.

Chart analysis

We don't have chart analysis for this company yet.

Competitors

We don't have competitor information for this company yet.

Circle of competence

We don't have circle of competence information for this company yet.